Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid.
Phase of Trial: Phase II/III
Latest Information Update: 20 Dec 2016
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV infections
- Focus Pharmacogenomic; Pharmacokinetics
- 06 Apr 2011 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
- 09 Aug 2010 Planned end date changed from Aug 2009 to Aug 2011 as reported by ClinicalTrials.gov.
- 21 May 2009 New source identified and integrated (Vanderbilt University Medical Center Clinical Trials Center).